Venetoclax with BUCY conditioning for high-risk AML or MDS transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding venetoclax (a pill that targets cancer cells) to the standard chemotherapy regimen before a stem cell transplant improves outcomes for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). It is for patients aged 12–60 whose cancer has specific high-risk features and who have a matched donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 60 years old.
- You have been diagnosed with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) based on specific genetic or other features.
- For AML, your disease must be in remission (complete remission or complete remission with incomplete blood count recovery) before the transplant.
- For MDS, your bone marrow must have less than 20% blasts (immature cells).
- You have a matched related or unrelated donor (9 or 10 out of 10 HLA match).
- Your heart, kidney, and liver function are good enough (as determined by standard tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
This study tests whether adding venetoclax to a specific busulfan-based chemotherapy plan improves outcomes for people with high-risk AML or MDS. It mainly targets patients whose leukemia/marrow disease still has high-risk features or measurable disease after initial treatment.
This trial tests adding venetoclax to a standard “conditioning” chemotherapy plan before an allogeneic stem cell transplant (using a donor) for certain bone marrow cancers. It aims to improve how well the transplant works and how safe this combination is for people with MDS, CMML, or sAML.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This study tests whether adding venetoclax (a targeted pill that helps kill leukemia cells) to a stem cell transplant, and continuing it afterward, improves outcomes compared to a placebo. It is for people with acute myeloid leukemia (AML) in their first remission who are getting a reduced-intensity transplant.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.